By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Monday said Tremfya met its primary endpoints in a pair of phase 3 studies in adults with active psoriatic arthritis.

Janssen said 24-week data showed a significantly greater proportion of patients treated with Tremfya achieved at least a 20% improvement in disease signs and symptoms compared with placebo.

The company said the data formed the basis of its recent U.S. and European regulatory filings seeking approval of Tremfya for psoriatic arthritis, a chronic disease characterized by joint inflammation and the skin lesions associated with psoriasis.

Janssen in 2017 received U.S. and European approval of Tremfya for adults with moderate to severe plaque psoriasis.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 11, 2019 09:12 ET (14:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Johnson and Johnson.